Member Info for avctIPmatters

No need for guesswork/conjecture just read the RNS : Placing old news .

https://www.lse.co.uk/rns/AVCT/oversubscribed-strategic-equity-fundraise-of-1639m-sgxskg528finfw7.html

----------------

"Christina Coughlin, CEO of Avacta commented:

"This Placing enables Avacta to retain the value of our equity while further reinforcing our financial position by reducing the outstanding debt in the Convertible Bond. Our cash runway provides sufficient funding to progress both clinical drug candidates from our industry-leading pre|CISION® technology through major clinical milestones and to move our Gen Three molecule into IND-enabling studies.

"The initial clinical data on the Gen Two program AVA6103 in late H2 2026, as well as further Phase 1 data on Gen One AVA6000 later this month at the BIO International Convention, mark key milestones for the Company, as we expect that these data will provide validation of our pre|CISION® technology in patients, by demonstrating that both our First and Second Gen molecules can effectively treat human cancers. In parallel, we continue to advance our partnering discussions, which are ongoing with multiple parties, on all three generations of our pre|CISION® platform."

The Company has chosen to strategically accept new investment into the business at the Issue Price of 70 pence, significantly higher than the potential share-based payment prices, thereby resulting in a reduction in potential shareholder dilution whilst strengthening the Company's balance sheet.

The net proceeds of the Placing will allow the Company to pay the Deferred Repayments in cash and, in addition, pay an additional quarterly payment in cash if required.

This Placing has allowed Avacta to have an enhanced balance sheet, and should the Deferred Repayments be accelerated and an additional quarterly repayment be paid in cash, the Convertible Bond would be reduced to approximately £11.5 million, which represents approximately 3.6 per cent of the market capitalisation of the Company immediately prior to this Announcement."

Gmcc

Sorry might have been posted previously -anyway nice mention for Avacta .

https://www.peptideandprotein.com/item/application%2F2026-05-26_oncology-peptides-future-outlook-macrocycles-radioligands-conjugates-vaccines.html?tags=[object+Object

------------

3. Conjugates and the Fibroblast Activation Protein Convergence

Peptide drug conjugates pair a targeting peptide with a cytotoxic or radioactive payload, and the most clinically advanced non-radioligand example is Avacta's faridoxorubicin (AVA6000). It uses a peptide that is cleaved by fibroblast activation protein in the tumor microenvironment to release doxorubicin locally, an approach designed to spare the heart from the cumulative cardiotoxicity that limits conventional doxorubicin. After durable responses in salivary gland cancer, the program had its lifetime maximum dose limit removed on cardiac-safety grounds in February, and the company raised additional capital in March to push expansion cohorts (Avacta Q1 2026 update).

The forward-looking theme here is convergence on fibroblast activation protein as a shared target across modalities. The same stromal protein that Avacta's peptide conjugate exploits for payload release is also a peptide radioligand target, with several lutetium-177, yttrium-90, and actinium-225 ligands in early clinical testing (Frontiers in Nuclear Medicine review, late 2025). One target, attacked by two peptide modalities, is exactly the kind of convergence that signals a maturing field."

Gmcc

Interesting article courtesy Stonks - Avacta Technology less side effects on it's own should be USP .

https://www.biospectrumasia.com/influencers/25/27861/the-companies-that-win-will-generate-better-decisions-not-just-more-molecules.html

Gmcc

--------

"Peptides sit in a valuable space between small molecules and antibodies. They can provide high-affinity, high-selectivity recognition while also being engineered for stability, tissue exposure, target engagement, and conjugation. Historically, peptides were viewed as limited by stability, permeability, and delivery. That view is becoming outdated. As the field develops better ways to stabilize peptide structures, screen very large chemical spaces, and build drug-like properties into peptide scaffolds earlier, peptides are becoming a serious therapeutic class for oncology targets that are not easily addressed by conventional modalities."

468.55m outstanding shares - less than 60m votes counted per resolution - do wonder if proxy votes actually included or even returned by Share Dealing Companies .

Gmcc

FYI Pharma Industry News : AI generated .

"Avacta targets late-2026 AVA6103 data as AVCT shifts from funding risk to clinical proof"

https://business-news-today.com/category/pharma-industry-news/

"The strategic opportunity is substantial because successful clinical validation could support licensing deals across multiple cancer medicines, but the investment case now depends less on platform theory and more on whether the emerging human data a re sufficiently convincing to attract pharmaceutical partners.!

Nothing new but fair enough review

"The immediate catalyst is the release of further AVA6000 data during the BIO International Convention. The market will assess whether the additional information strengthens the earlier salivary gland cancer signals and whether responses remain durable as more follow-up becomes available."

Gmcc

"

https://x.com/coughlin582/status/2069064393560559745

Christina Coughlin

@coughlin582

·

22m

My worlds are colliding. Walked out of my AGM today with a head full of feedback and a determined spirit on the “work side” of my brain. Then this is a first post …

Phillies sent the Mets home in fantastic style this week .. now this?

What if both worlds could #Ringthebell"

Gmcc

Good Morning

https://avacta.wistia.com/s/shx67w0ggjx8jel

Avacta

@avacta

In the 3rd Episode of Avacta Academy, our CEO Chris Coughlin and CSO Francis Wilson speak to the CMC team to explain the nuts and bolts of how a drug moves from the lab to being a medicine, and break down the GMP drug manufacturing process. https://avacta.wistia.com/s/shx67w0ggjx8jel

Gmcc

Might be of interest

--------------

Courtesy Marty McFly

@Blueberrymgmnt

TLDR; The future of ADCs depends less on the antibody and more on tumour biology, shifting focus from tumour-cell targeting to biomarkers, spatial biology, resistance, linker chemistry, payload selection and the TME.

@avacta

’s pre|CISION platform is built for this future. #AVCT

Quote

Raffaele Colombo

@raffcolo

·

13h

Selecting the right ADC for the right patient will increasingly depend on biomarkers, especially with so many ADCs sharing similar payloads.

Led by @BarbaraPistill2, we discussed this challenge and the need for better biomarkers in our @cancercell review

https://x.com/Blueberrymgmnt/status/2066980508089606431

https://www.cell.com/cancer-cell/fulltext/S1535-6108(26)00249-7

Gmcc

Avacta seems to have a good working mutual relationship with Venture Road program, guess exposure helps widen commercial /investment interest in Avacta technology .

https://www.pharma-industry.se/anti-cancer-drug-company-wins-pitching-competition/

Gmcc

Worth a listen

https://x.com/avacta/status/2066912453271650586

"

Avacta

@avacta

·

4m

In this interview with Ventures Accelerated Life Science, Avacta CEO

@coughlin582

shares how Avacta is redefining precision oncology with its tumor-targeted delivery platform, and why this matters for patients, clinicians, and partners. https://linkedin.com/posts/last-thursday-during-venture-road-uk-companies-ugcPost-7472572167377858560-8u_q #AVCT"

Gmcc

Slightly different version this one

https://www.linkedin.com/company/ventures-accelerated-life-science/posts/

Ventures Accelerated Life ScienceVentures Accelerated Life Science

1,133 followers1,133 followers

5h • 5 hours ago • Visible to anyone on or off LinkedIn

Follow

Last Thursday during Venture Road UK, companies from across the Nordics and the UK pitched in front of a mixed audience of investors and industry partners. Our warm congratulations to the winner of the pitch session, Christina Coughlin, CEO of Avacta Therapeutics, who is working on targeted cancer therapy delivery to improve efficacy while reducing side effects for patients.

In this short interview, Christina shares how Avacta is redefining precision oncology with its tumor-targeted delivery platform, and why this matters for patients, clinicians, and partners. She also talks about the story behind Avacta’s approach, how they communicate complex science in a clear value narrative for investors and pharma, and what she sees as the most important ingredients for successful Nordic–UK collaboration in oncology innovation.

rgeted delivery platform, and why this matters for patients, clinicians, and partners. She also talks about the story behind Avacta’s approach, how they communicate complex science in a clear value narrative for investors and pharma, and what she sees as the most important ingredients for successful Nordic–UK collaboration in oncology innovation."

Gmcc

RNS "The study continues to enroll patients and Avacta plans to present further data on the AVA6000 program at BIO International Convention, taking place June 22-25, 2026 in San Diego, CA, USA."

BIO Partnering™

Hundreds of Participating Investors attending - hopefully be a few interested /invited to hear about benefits of Avacta technology . AVA6000 clinical data + future pipeline etc. Private one to one discussions .

https://convention.bio.org/partner/participating-investors?&filters.investor=YES&searchgroup=0D1C8829-participating-companies.

Gmcc

Good Morning : Avacta listed page 6

https://convention.bio.org/partner/participating-companies?&page=6&searchgroup=7CFEA488-participating-companies

Gmcc

Obviously clinicians involved with treating patients in clinical trials very supportive of Avacta Technology .

Also others for example :"Bench Chemicals, aka. BenchChem, is a leading supplier of high-quality chemicals and biochemicals for laboratory and R&D use. Our mission is to be the trusted global source of essential and advanced chemicals, empowering scientists and researchers to drive progress in science and industry. "

Review paper : " Early-phase clinical trial results for AVA6000

Author: BenchChem Technical Support Team. Date: April 2026

https://pdf.benchchem.com/15611/Early_phase_clinical_trial_results_for_AVA6000.pdf

Might be of interest :

"Conclusion and Future Directions

The early-phase clinical data for AVA6000 are highly promising. The results provide strong clinical proof-of-concept for the pre|CISION™ platform, demonstrating that FAP-activated targeted release of doxorubicin can deliver the chemotherapy agent effectively to the tumor while significantly improving its safety and tolerability profile.[17] The observed anti-tumor activity, especially the durable responses in heavily pre-treated patients with salivary gland cancer and soft tissue sarcoma, highlights the therapeutic potential of AVA6000.[14][18] The ongoing Phase 1b expansion cohorts will provide further data on efficacy in specific indications.[15][21] These results will inform the design of a pivotal Phase 2 efficacy study, with the goal of providing a new, effective, and safer treatment option for patients with FAP-positive solid tumors.[19]

https://www.benchchem.com/

Owning the IP assets is a huge Avacta + factor IMO : Getting endorsement from different sources helps . The Avacta story still a few chapters left but convinced will indeed be a very happy ending foe shareholders & cancer patients .

Gmcc

Try this link

https://x.com/JStonker/status/2065003222813540580/photo/1

#AVCT's presentation was "the strongest of the day"

https://linkedin.com/posts/olivia-bachs-theng-bb0a3b28b_ventureroaduk-ugcPost-7470765927534546944-Rze9

Courtesy Stonks

FYI :

https://www.linkedin.com/company/avacta/posts/?feedView=all

Avacta TherapeuticsAvacta Therapeutics

8,781 followers8,781 followers

1h • 1 hour ago • Visible to anyone on or off LinkedIn

This week we were in London for Venture Road UK 2026, joining the life sciences community to share the progress of our pre|CISION® platform.

Our tumor-activated peptide drug conjugates are designed to do something powerful: stay silent in the bloodstream and switch on inside the tumor, delivering potent therapy precisely where it is needed while sparing healthy tissue.

With AVA6000 showing early efficacy signals in salivary gland cancers, AVA6103 now dosing patients in the FOCUS-01 Phase 1 trial, and our dual-payload AVA6207 advancing through preclinical development, we look forward to the conversations ahead.

hashtag#preCISION hashtag#Oncology hashtag#Biotech hashtag#Biopharma hashtag#HopeWithoutCompromise

Gmcc

Good Morning

Firmly believe one day Avacta science will be treating many cancer patients & shareholders will be rewarded when will it happen i know not.

As I reach 80 years this week hopefully sooner than later - Did say I would review my position June 2026 .

Avacta market cap did briefly get to around £400m a few weeks back will admit a nice feeling to be in paper profit so disappointing to be back in cash deficit .

CC did mention she expected inflection points being hit 2H 2026 so have decided to hold onto all my shares & see what transpires ,

Still expect AVA6000 will find licence partners. As far better /safer dox solution for selected cancer candidates .If not partnered assume existing AVA6000 Phase one patients will continue to be treated -but phase 2 will be moth balled .

Either way allows company to concentrate on AVA6103 the blockbuster invention +progress the pipeline.

Certainly a lot of monotonous repetition posted here , myself included . Never bother filtering easy to ignore the usual suspects . Do however appreciate the info /new research links shared by many thanks .

Good luck everyone

Gmcc

CC AVA6103 obviously her baby "The Beast " CC keen to concentrate on Next Gen pipeline assets . AVA6000 will get partnered .RNS today buys some leeway still expect AVA6000 candidate assets will generate value ,

CC earns :

"On April 30, 2024, Christina Coughlin was appointed Chief Executive Officer of Avacta Group, with her basic salary being set at $515,000 per annum reflecting the level of experience that Christina brings to the role and comparable salaries across US and European biotech companies. In addition to the basic salary, a one-off fee of $225,000 was paid to Christina on commencement of the role.

Christina Coughlin, with her appointment as Chief Executive Officer was awarded 3,600,000 options with a strike price of 72p

Note 1—The option shall become exercisable over a maximum of 3,600,000 shares as follows: 1,200,000

shares will vest on 1 May 2025, 1,200,000 shares will vest on 1 May 2026, 1,200,000 shares will vest on 1 May 2027."

Gmcc

Note new appointment

Kim Hart Paulsen

She/Her

Vice President Clinical Operations at Avacta Therapeutics

Riverton, New Jersey, United States

-------------------

"Over 25 years of cross-functional leadership in phases I-IV global clinical operations, specializing in oncology and hematology trials, ensuring compliance with regulatory standards and delivering projects on time and within budget. Possess a broad understanding of the bigger picture and how clinical operations and development works across all functions. Experience in programs from IND to NDA Submission, pinpointing resource requirements, and evaluating operational quality and risk spanning biotechnology companies, pharmaceutical companies, clinical research organizations, and the site level.

Areas of Expertise: Strategic cross-functional leadership, SOP development, Regulatory strategy development and compliance, Clinical trial design and management, Budget forecasting, Project planning, Risk assessment, Vendor selection and management, Advanced clinical data analysis, Hematology/ Oncology

Top skills

Clinical Trials • Cross-functional Team Leadership • Regulatory Strategy Development • Portfolio Optimization • Clinical Study Design

Vice President Clinical Operations

Avacta Therapeutics · Full-time

Jun 2026 - Present · 1 month

London, United Kingdom · Remote

https://www.linkedin.com/in/kim-hart-paulsen-9949386/

--------------------------